论文部分内容阅读
目的观察多西他赛联合奥沙利铂/卡培他滨治疗晚期胃癌的近期疗效和不良反应。方法47例晚期胃癌患者采用多西他赛60 mg/m~2,静脉滴注,第1天;奥沙利铂85 mg/m~2,静脉滴注,第2天;卡培他滨2000 mg/m~2,bid,口服,服10 d停4 d,14 d为1周期。3周期后评价疗效和不良反应。结果全组47例患者均可评价疗效,其中CR 4例(8.5%),PR 24例(51.1%),SD 12例(25.5%),PD 7例(14.9%),总有效率59.6%,Ⅲ/Ⅳ度中性粒细胞减少发生率51.1%。中位TTP为6.2个月(3.4～11.6个月),中位OS为11.3个月(5.9～14.6个月)。结论多西他赛联合奥沙利铂/卡培他滨治疗晚期胃癌有效率较高,血液学毒性低,近期疗效较好,用药方便、安全,明显提高了患者的生活质量。
Objective To observe the short-term efficacy and side effects of docetaxel plus oxaliplatin / capecitabine in the treatment of advanced gastric cancer. Methods Forty-seven patients with advanced gastric cancer were treated with docetaxel 60 mg / m 2, intravenously on day 1, oxaliplatin 85 mg / m 2, intravenously on day 2, capecitabine 2000 mg / m ~ 2, bid, orally, serving 10 d stop 4 d, 14 d for 1 cycle. Three cycles after the evaluation of efficacy and adverse reactions. Results There were 47 patients with CR (8.5%) in CR, 24 (51.1%) in PR, 12 (25.5%) in SD and 7 (14.9%) in PD with a total effective rate of 59.6% Ⅲ / Ⅳ degree of neutropenia incidence of 51.1%. The median TTP was 6.2 months (3.4 to 11.6 months) and the median OS was 11.3 months (5.9 to 14.6 months). Conclusion Docetaxel combined with oxaliplatin / capecitabine in the treatment of advanced gastric cancer has high efficiency, low hematological toxicity and good curative effect in the near future. It is convenient and safe to use, and obviously improves the quality of life of patients.